Identifying and Validating Biomarkers to Develop Truly Disease Modifying Therapeutics for Alzheimer’s Disease

The Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement.

With an emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this industry-defining meeting delves into blood-based biomarkers, neuroinflammatory markers, NFL, microglial activation, exosomes and CSF synaptic biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s.

The Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science, convey lessons learned and network to build long lasting partnerships.  

Thank you to our speakers, sponsors and delegates who joined us for the online summit! If you are interested in the 2020 event, please get in touch as

World-Class Speaker Faculty Includes:

Danielle Graham

Senior Director, Discovery & Clinical Biomarkers


Scott Shandler

Founder & CEO

Longevity Biotech

Rhoda Au

Professor of Anatomy, Neurobiology

Framingham Heart Study, Boston University Schools of Medicine

Jonathan Levenson

Vice President of Translational Biology

Tiaki Therapeutics

Mark Frasier

Senior Vice President

Research Programs Michael J Fox Foundation

Other Events in the World CNS Series: